# Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

> **NCT04639739** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 9 (estimated)

## Conditions studied

- NHL

## Interventions

- **BIOLOGICAL:** anti-CD19 CAR NK

## Key facts

- **NCT ID:** NCT04639739
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-17
- **Primary completion:** 2021-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2020-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639739, "Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT04639739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*